Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 19, 2023
Daily News
October 19, 2023
- Takeda to Pay 130 Million Euro to Settle Tax Row over Shire-AbbVie Breakup Fee
October 19, 2023
- Japan to Buy 10 Million More Doses of Pfizer/Moderna COVID Jabs
October 19, 2023
- Takeda’s 1st Cell Therapy Alofisel Misses Goal in Key PIII Study
October 19, 2023
- Diazepam Nasal Spray Shows Efficacy in PIII Interim Analysis: Aculys
October 19, 2023
- Health Minister Requests 8 Makers to Bolster Supplies of Antitussive, Expectorant Agents
October 19, 2023
- Leqembi’s Initial Pricing Won’t Factor in Benefits in Long-Term Care
October 19, 2023
- Chuikyo at Odds over Handling of Startups in PMP, Timing of Deferred Price Cuts
October 19, 2023
- Fuji Pharma/M3’s Dysmenorrhea Drug Filed in Japan, 2024 Rollout Targeted
October 19, 2023
- Herceptin Biosimilars Get Colorectal Cancer Nod: Celltrion, Nippon Kayaku
October 19, 2023
- Daiichi Sankyo Ordered to Pay 8% Royalty to Seagen in ADC Patent Row
October 19, 2023
- BMS Looks to Double Japan Biz in Next 10 Years with Partnership as a Pillar
October 19, 2023
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…